SCHEMBL10030474

SCHEMBL10030474

Cc1cccc(Oc2ccc(C(C)(C)C)cc2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
HTT P42858 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MAPT P10636 3/20 0.53
HPGD P15428 2/20 0.53
MAPK1 P28482 2/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
ACHE P22303 1/20 0.48
AR P10275 2/20 0.48
HSD17B1 P14061 1/20 0.47
HSD17B2 P37059 1/20 0.47
RAF1 P04049 1/20 0.46
GAA P10253 2/20 0.46
ADAMTS5 Q9UNA0 2/20 0.46
RECQL P46063 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TSHR P16473 1/20 0.45
GFER P55789 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12755245 0.89 ALDH1A1 (0.62) ALDH1A1HTTTDP1L3MBTL1MAPT
SCHEMBL12879327 0.87 ALDH1A1 (0.55) ALDH1A1HTTTDP1L3MBTL1MAPT
SCHEMBL10013917 0.86 ALDH1A1 (0.80) ALDH1A1HTTTDP1L3MBTL1MAPT
SCHEMBL14159539 0.86 ALDH1A1 (0.80) ALDH1A1HTTTDP1L3MBTL1MAPT
SCHEMBL22959442 0.86 ALDH1A1 (0.59) ALDH1A1HTTTDP1L3MBTL1MAPK1
SCHEMBL13474891 0.85 MAPT (0.57) ALDH1A1HTTL3MBTL1MAPTHPGD
SCHEMBL11161978 0.84 ALDH1A1 (0.61) ALDH1A1HTTTDP1L3MBTL1MAPT
SCHEMBL14159535 0.83 ALDH1A1 (0.56) ALDH1A1HTTTDP1L3MBTL1MAPT
SCHEMBL3239088 0.82 ALDH1A1 (0.64) ALDH1A1TDP1MAPTHPGDMAPK1
SCHEMBL822034 0.82 ALDH1A1 (0.74) ALDH1A1HTTTDP1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024044098-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-29 WO disclosed
US-20230159578-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-05-25 US disclosed
US-10875852-B2 Heteroaromatic compounds as BTK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-12-29 US disclosed
US-20190112302-A1 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2019-04-18 US disclosed
US-20170320867-A1 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2017-11-09 US disclosed
US-20170320867-A1 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2017-11-09 US disclosed
US-9486422-B2 Small molecule inhibitors of Mcl-1 and the uses of thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-11-08 US disclosed
US-9309260-B2 Inhibitors of hepatitis C virus PRESIDIO PHARMACEUTICALS, INC. (US) 2016-04-12 US disclosed
US-20160031872-A1 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2016-02-04 US disclosed
US-20160031872-A1 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2016-02-04 US disclosed
US-20120276051-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. (US) 2012-11-01 US disclosed
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. 2012-10-04 US disclosed
US-20120160317-A1 POLYIMIDE POLYMER SOLUTION, POLYIMIDE POLYMER, TRANSPARENT FILM, DISPLAYING DEVICE AND SOLAR CELL INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2012-06-28 US disclosed
US-20110301192-A1 Inhibitors of Cyclin Kinase Inhibitor p21 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-12-08 US disclosed
US-7932283-B2 Fungicide N-cyclopropyl-sulfonylamide derivatives BAYER CROPSCIENCE AG (DE) 2011-04-26 US disclosed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
US-20090137611-A1 Fungicide N-Cyclopropyl-Sulfonylamide Derivatives BAYER CROPSCIENCE AG (DE) 2009-05-28 US disclosed
US-7238688-B2 Piperidine compounds SCHERING CORPORATION (US) 2007-07-03 US disclosed
US-7169782-B2 Aryl substituted thiazolidinones and the use thereof EURO-CELTIQUE S.A. (LU) 2007-01-30 US disclosed
US-7169782-B2 Aryl substituted thiazolidinones and the use thereof EURO-CELTIQUE S.A. (LU) 2007-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120276051-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, LIPC, HCCS ALDH1A1 1654/4885HTT 4258/4885TDP1 4045/4885
US-20110301192-A1 Inhibitors of Cyclin Kinase Inhibitor p21 CDKN1A, CCNI, CDK2 ALDH1A1 1470/4885HTT 3934/4885TDP1 1148/4885
US-20170320867-A1 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS BTK, SYK, LCK ALDH1A1 3329/4885HTT 3080/4885TDP1 672/4885
US-20230159578-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OXER1, OPRD1, DRD3 ALDH1A1 710/4885HTT 3177/4885TDP1 2263/4885
US-20090137611-A1 Fungicide N-Cyclopropyl-Sulfonylamide Derivatives CYP51A1, ERG28, CBR3 ALDH1A1 2140/4885HTT 1957/4885TDP1 2473/4885
US-20160031872-A1 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS BTK, SYK, LCK ALDH1A1 3329/4885HTT 3080/4885TDP1 672/4885
US-10875852-B2 Heteroaromatic compounds as BTK inhibitors BTK, SYK, LCK ALDH1A1 3329/4885HTT 3080/4885TDP1 672/4885
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, LIPC, HCCS ALDH1A1 1654/4885HTT 4258/4885TDP1 4045/4885
US-20190112302-A1 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS BTK, SYK, LCK ALDH1A1 3329/4885HTT 3080/4885TDP1 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.